aristoforin and hyperforin

aristoforin has been researched along with hyperforin* in 6 studies

Other Studies

6 other study(ies) available for aristoforin and hyperforin

ArticleYear
Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 81

    Our previous results have shown that the combination of hypericin-mediated photodynamic therapy (HY-PDT) at sub-optimal dose with hyperforin (HP) (compounds of Hypericum sp.), or its stable derivative aristoforin (AR) stimulates generation of reactive oxygen species (ROS) leading to antitumour activity. This enhanced oxidative stress evoked the need for an explanation for HY accumulation in colon cancer cells pretreated with HP or AR. Generally, the therapeutic efficacy of chemotherapeutics is limited by drug resistance related to the overexpression of drug efflux transporters in tumour cells. Therefore, the impact of non-activated hypericin (HY), HY-PDT, HP and AR on cell membrane transporter systems (Multidrug resistance-associated protein 1-MRP1/ABCC1, Multidrug resistance-associated protein 2-MRP2/ABCC2, Breast cancer resistance protein - BCRP/ABCG2, P-glycoprotein-P-gp/ABCC1) and cytochrome P450 3A4 (CYP3A4) was evaluated. The different effects of the three compounds on their expression, protein level and activity was determined under specific PDT light (T0+, T6+) or dark conditions (T0- T6-). We found that HP or AR treatment affected the protein levels of MRP2 and P-gp, whereas HP decreased MRP2 and P-gp expression mostly in the T0+ and T6+ conditions, while AR decreased MRP2 in T0- and T6+. Moreover, HY-PDT treatment induced the expression of MRP1. Our data demonstrate that HP or AR treatment in light or dark PDT conditions had an inhibitory effect on the activity of individual membrane transport proteins and significantly decreased CYP3A4 activity in HT-29 cells. We found that HP or AR significantly affected intracellular accumulation of HY in HT-29 colon adenocarcinoma cells. These results suggest that HY, HP and AR might affect the efficiency of anti-cancer drugs, through interaction with membrane transporters and CYP3A4.

    Topics: Adenocarcinoma; Anthracenes; Blotting, Western; Cell Line, Tumor; Colonic Neoplasms; Cytochrome P-450 CYP3A; Firefly Luciferin; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Perylene; Phloroglucinol; Real-Time Polymerase Chain Reaction; Terpenes

2016
DNA-protective activities of hyperforin and aristoforin.
    Toxicology in vitro : an international journal published in association with BIBRA, 2015, Volume: 29, Issue:3

    The aim of this study was to explain the molecular mechanisms of action of hyperforin, a phluoroglucinol derivative found in Hypericum perforatum L. and its more stable derivative aristoforin. DNA-topology assay revealed partial DNA-protective activities of hyperforin and aristoforin against Fe(2+)-induced DNA breaks. In order to assess molecular mechanisms underlying DNA-protective activity, the potential antioxidant activity of hyperforin and aristoforin was investigated using DPPH and OH scavenging assays, reducing power assay and Fe(2+)-chelating assay. We also studied interaction of hyperforin and aristoforin with DNA using established protocols for fluorescence titration. The ability of the studied compounds to relax topoisomerase I with electrophoretic techniques was investigated. The reduction in the fluorescence of hyperforin indicated an interaction between hyperforin and DNA with a binding constant of 0.2×10(8)M(-1). We suggest that a mechanism of hyperforin/aristoforin DNA-protective abilities is based on free radicals (mainly OH) scavenging activity.

    Topics: Antioxidants; DNA; DNA Breaks; Free Radical Scavengers; Hypericum; Iron; Iron Chelating Agents; Phloroglucinol; Terpenes; Topoisomerase I Inhibitors

2015
The pro-apoptotic and anti-invasive effects of hypericin-mediated photodynamic therapy are enhanced by hyperforin or aristoforin in HT-29 colon adenocarcinoma cells.
    Journal of photochemistry and photobiology. B, Biology, 2012, Dec-05, Volume: 117

    Photodynamic therapy is a rapidly-developing anti-cancer approach for the treatment of various types of malignant as well as non-malignant diseases. In this study, hypericin-mediated photodynamic therapy (HY-PDT) in sub-optimal dose was combined with hyperforin (HP) or its stable derivative aristoforin (AR) in an effort to improve efficacy on the cellular level. The logic of this combination is based on the fact that both bioactive compounds naturally occur in plants of Hypericum sp. At relatively low concentrations up to 5 μM, hyperforin and aristoforin were able to stimulate onset of apoptosis in HT-29 colon adenocarcinoma cells exposed to HY-PDT, inhibit cell cycle progression, suppress expression of matrixmetalloproteinases-2/-9 together with cell adhesivity, thereby affecting the clonogenic potential of the cells. As the action of aristoforin was more pronounced, in line with our assumption, these changes were also linked in this case with hypericin accumulation and increased ROS generation leading to dissipation of mitochondrial membrane potential in a significant portion of the cells, as well as activation of caspase-3. Comparison of HT-29 cells to another colon adenocarcinoma-derived cell line HCT-116 demonstrated significant differences in sensitivity of different cell lines to PDT, however, accumulated effect of HY-PDT with HP/AR proved similar in both tested cell lines. The presented data may help to elucidate the mechanisms of action for different bioactive constituents of St. John's wort, which are increasingly recognized as being able to regulate a variety of pathobiological processes, thus possessing potential therapeutic properties.

    Topics: Adenocarcinoma; Anthracenes; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Intracellular Space; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Perylene; Phloroglucinol; Photochemotherapy; Reactive Oxygen Species; Terpenes

2012
Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
    International journal of cancer, 2009, Jul-01, Volume: 125, Issue:1

    The phloroglucinol derivative hyperforin, a major bioactive constituent of St. John's wort, is increasingly recognized as being able to regulate a variety of pathobiological processes and, thus, to possess potential therapeutic properties. In the context of cancer, hyperforin induces the apoptosis of cancer cells, inhibits angiogenesis and suppresses metastasis formation. Here, we report a new pharmacological function of hyperforin and its stabilized derivative aristoforin, namely the suppression of lymphatic endothelial cell (LEC) growth and lymphangiogenesis. At concentrations less than 10 microM, we found that these compounds induce cell cycle arrest of LECs, and at higher concentrations induce apoptosis. The loss of mitochondrial membrane potential and the activation of caspase-9 during the induction of apoptosis indicate that the intrinsic pathway of apoptosis is stimulated by these compounds, similar to the situation in tumor cells. In thoracic duct ring outgrowth assays, hyperforin and aristoforin both inhibited lymphangiogenesis, as evidenced by the suppression of lymphatic capillary outgrowth. In an in vivo animal model, both compounds were able to inhibit tumor-induced lymphangiogenesis. Together these data substantiate a new role for hyperforin and its derivatives as suppressors of lymphangiogenesis, and support their further investigation as potential anticancer drugs that target tumor growth and metastasis at multiple levels.

    Topics: Animals; Aorta, Thoracic; Apoptosis; Bridged Bicyclo Compounds; Caspase 3; Caspase 8; Cell Cycle; Cell Proliferation; Cells, Cultured; Cytochromes c; Endothelial Cells; Endothelium, Vascular; Female; Humans; In Vitro Techniques; Lymphangiogenesis; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms, Experimental; Phloroglucinol; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Terpenes; Xenograft Model Antitumor Assays

2009
Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2.
    Angewandte Chemie (International ed. in English), 2007, Volume: 46, Issue:27

    Topics: Bridged Bicyclo Compounds; Cell Proliferation; Cells, Cultured; Humans; Magnetic Resonance Spectroscopy; Molecular Structure; Phloroglucinol; Sirtuin 1; Sirtuin 2; Sirtuins; Terpenes

2007
Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent.
    Chembiochem : a European journal of chemical biology, 2005, Volume: 6, Issue:1

    Hyperforin, a natural product of St. John's wort (Hypericum perforatum L.), has a number of pharmacological activities, including antidepressive and antibacterial properties. Furthermore, hyperforin has pronounced antitumor properties against different tumor cell lines, both in vitro and in vivo. Despite being a promising novel anticancer agent, the poor solubility and stability of hyperforin in aqueous solution limits its potential clinical application. In this study, we present the synthesis of hyperforin derivatives with improved pharmacological activity. The synthesized compounds were tested for their solubility and stability properties. They were also investigated for their antitumor properties, both in vitro and in vivo. One of these hyperforin derivatives, Aristoforin, is more soluble in aqueous solution than hyperforin and is additionally highly stable. Importantly, it retains the antitumor properties of the parental compound without inducing toxicity in experimental animals. These data strongly suggest that Aristoforin has potential as an anticancer drug.

    Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds; Drug Stability; Phloroglucinol; Rats; Solubility; Terpenes

2005